Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines

Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have recently been reported in many countries. These have exacerbated the coronavirus disease 2019 (COVID-19)-induced global health threats and hindered COVID-19 vaccine development and therapeutic progress. This commentar...

Full description

Bibliographic Details
Main Authors: Md. Jamal Hossain, Ali A. Rabaan, Abbas Al Mutair, Saad Alhumaid, Talha Bin Emran, G Saikumar, Saikat Mitra, Kuldeep Dhama
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
sars-cov-2 b.1.621
sub-lineage b.1.621.1
mu variant
vaccine breakthrough
genomic surveillance
global mass vaccination
non-pharmaceutical interventions (npis)
Online Access:http://dx.doi.org/10.1080/21645515.2022.2027197

Internet

http://dx.doi.org/10.1080/21645515.2022.2027197

Similar Items